Considering the potential role of DPP4 inhibitors as additional therapeutic agents in current HCC treatment, it should also be noted that the combination of a DPP4 inhibitor (sitagliptin) and an anti-PD1 antibody improved anti-tumor immunity in immunocompetent mice [33]. Here, DPP4 is linked to neoplasm.